These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12164770)

  • 1. Integrating pharmacogenomics into drug development.
    Ferentz AE
    Pharmacogenomics; 2002 Jul; 3(4):453-67. PubMed ID: 12164770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacogenomics: the quest for individualized therapy].
    López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME
    Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current pharmacogenomic approaches to clinical drug development.
    Murphy MP
    Pharmacogenomics; 2000 May; 1(2):115-23. PubMed ID: 11256585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach.
    Mandry T
    Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in pharmacogenomics and its promise for medicine.
    Blake CA; Sobel BE
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics at 50: genomic personalization comes of age.
    Urban TJ; Goldstein DB
    Sci Transl Med; 2014 Jan; 6(220):220ps1. PubMed ID: 24452261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should pharmacogenomic studies be required for new drug approval?
    Relling MV; Hoffman JM
    Clin Pharmacol Ther; 2007 Mar; 81(3):425-8. PubMed ID: 17339872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
    Zineh I; Pacanowski MA
    Pharmacotherapy; 2011 Aug; 31(8):729-35. PubMed ID: 21923598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics and cost-effectiveness analysis: a two-way street.
    Chalkidou K; Rawlins M
    Drug Discov Today; 2011 Oct; 16(19-20):873-7. PubMed ID: 21903176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HapMap, pharmacogenomics, and the goal of personalized prescribing.
    O'Shaughnessy KM
    Br J Clin Pharmacol; 2006 Jun; 61(6):783-6. PubMed ID: 16722846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Payer perspectives on pharmacogenomics testing and drug development.
    Epstein RS; Frueh FW; Geren D; Hummer D; McKibbin S; O'Connor S; Randhawa G; Zelman B
    Pharmacogenomics; 2009 Jan; 10(1):149-51. PubMed ID: 19102724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I).
    Preskorn SH; Hatt CR
    J Psychiatr Pract; 2013 Mar; 19(2):142-9. PubMed ID: 23507814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development.
    Lee W; Lockhart AC; Kim RB; Rothenberg ML
    Oncologist; 2005 Feb; 10(2):104-11. PubMed ID: 15709212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. deCODE genetics, Inc.
    Hakonarson H; Gulcher JR; Stefansson K
    Pharmacogenomics; 2003 Mar; 4(2):209-15. PubMed ID: 12605555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics: the genomics of drug response.
    March R
    Yeast; 2000 Apr; 17(1):16-21. PubMed ID: 10797598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ontogeny and drug metabolism in newborns.
    Dotta A; Chukhlantseva N
    J Matern Fetal Neonatal Med; 2012 Oct; 25 Suppl 4():83-4. PubMed ID: 22958028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications.
    Abdel-Hamid IA; Andersson KE
    Pharmacogenomics; 2009 Oct; 10(10):1625-44. PubMed ID: 19842936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the development of genetic markers for the diagnosis of disease and drug response.
    Halapi E; Hakonarson H
    Expert Rev Mol Diagn; 2002 Sep; 2(5):411-21. PubMed ID: 12271813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of pharmacogenomics.
    Somogy A
    Proc West Pharmacol Soc; 2008; 51():1-4. PubMed ID: 19544663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.